June 24, 2019
Joshua Gagne
Associate Professor
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School
Department of Epidemiology, Harvard T.H. Chan School of Public Health
Contact
Recent Publications
- Methodologic considerations for noninterventional studies of switching from reference biologic to biosimilars
- Controlling Confounding in a Study of Oral Anticoagulants: Comparing Disease Risk Scores Developed Using Different Follow-Up Approaches
- Non-Vitamin K Antagonist Oral Anticoagulants and Angioedema: A Cohort and Case-Crossover Study
-
@JeffreyBrinson My understanding is that this pertains to all ranitidine products, including intravenous forms.
-
FDA requests removal of all ranitidine (Zantac) products from the market -- both prescription and over-the-counter versions. t.co/hJKFqYpkH8
-
New retrospective cohort study finds that apixaban may be superior to rivaroxaban for nonvalvular #afib—with lower rates of ischemic stroke or systemic embolism and less bleeding (GI or intracranial hemorrhage). @FralickMike @JoshuaJGagne @AnnalsofIM t.co/VAWEQ1qKxE
-
FDA: don’t take drugs intended for fish t.co/SJdQiTTyN6
-
Re-upping this. One week left and we're half way to our goal! Help folks who need food during the #COVID2019 pandemic and get this awesome t-shirt. Kudos to @AllieSosinsky for making this happen! #epitwitter #RxEpi t.co/UzWKKeTl7h t.co/mH14bhBWvx